Literature DB >> 28945471

Host-Pathogen Interactions and Chronic Lung Allograft Dysfunction.

John Belperio1, Scott M Palmer2, S Sam Weigt1.   

Abstract

Lung transplantation is now considered to be a therapeutic option for patients with advanced-stage lung diseases. Unfortunately, due to post-transplant complications, both infectious and noninfectious, it is only a treatment and not a cure. Infections (e.g., bacterial, viral, and fungal) in the immunosuppressed lung transplant recipient are a common cause of mortality post transplant. Infections have more recently been explored as factors contributing to the risk of chronic lung allograft dysfunction (CLAD). Each major class of infection-(1) bacterial (Staphylococcus aureus and Pseudomonas aeruginosa); (2) viral (cytomegalovirus and community-acquired respiratory viruses); and (3) fungal (Aspergillus)-has been associated with the development of CLAD. Mechanistically, the microbe seems to be interacting with the allograft cells, stimulating the induction of chemokines, which recruit recipient leukocytes to the graft. The recipient leukocyte interactions with the microbe further up-regulate chemokines, amplifying the influx of allograft-infiltrating mononuclear cells. These events can promote recipient leukocytes to interact with the allograft, triggering an alloresponse and graft dysfunction. Overall, interactions between the microbe-allograft-host immune system alters chemokine production, which, in part, plays a role in the pathobiology of CLAD and mortality due to CLAD.

Entities:  

Keywords:  bacteria; chronic lung allograft dysfunction; fungus; lung transplant; virus

Mesh:

Substances:

Year:  2017        PMID: 28945471      PMCID: PMC5711338          DOI: 10.1513/AnnalsATS.201606-464MG

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  29 in total

Review 1.  Chronic lung allograft rejection: mechanisms and therapy.

Authors:  John A Belperio; S Samuel Weigt; Michael C Fishbein; Joseph P Lynch
Journal:  Proc Am Thorac Soc       Date:  2009-01-15

Review 2.  Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment.

Authors:  S Samuel Weigt; W Dean Wallace; Ariss Derhovanessian; Rajan Saggar; Rajeev Saggar; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

3.  Staphylococcus via an interaction with the ELR+ CXC chemokine ENA-78 is associated with BOS.

Authors:  A L Gregson; X Wang; P Injean; S S Weigt; M Shino; D Sayah; A DerHovanessian; J P Lynch; D J Ross; R Saggar; A Ardehali; G Li; R Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2015-02-12       Impact factor: 8.086

4.  Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Brigitte Gomperts; Ying Ying Xue; Kurt Hong; Javier Mestas; Abbas Ardehali; Borna Mehrad; Rajan Saggar; Joseph P Lynch; David J Ross; Robert M Strieter
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 5.  Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Authors:  S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

6.  Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome.

Authors:  J A Belperio; M P Keane; M D Burdick; J P Lynch; Y Y Xue; A Berlin; D J Ross; S L Kunkel; I F Charo; R M Strieter
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

7.  Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome.

Authors:  Dana L Willner; Philip Hugenholtz; Stephanie T Yerkovich; Maxine E Tan; Joshua N Daly; Nancy Lachner; Peter M Hopkins; Daniel C Chambers
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

8.  Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

Authors:  Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

9.  Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes.

Authors:  Ryan K Shields; Cornelius J Clancy; Lucio R Minces; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Yoshiya Toyoda; Christian Bermudez; Jay K Bhama; Norihisa Shigemura; Joseph M Pilewski; Maria Crespo; M Hong Nguyen
Journal:  J Heart Lung Transplant       Date:  2012-09-15       Impact factor: 10.247

10.  CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction.

Authors:  Michael Y Shino; S Samuel Weigt; Ning Li; Vyacheslav Palchevskiy; Ariss Derhovanessian; Rajan Saggar; David M Sayah; Aric L Gregson; Michael C Fishbein; Abbas Ardehali; David J Ross; Joseph P Lynch; Robert M Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

View more
  10 in total

Review 1.  The role of the immune system in lung transplantation: towards improved long-term results.

Authors:  Ramsey R Hachem
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 2.  Influence of the microbiome on solid organ transplant survival.

Authors:  Isabella Pirozzolo; Zhipeng Li; Martin Sepulveda; Maria-Luisa Alegre
Journal:  J Heart Lung Transplant       Date:  2021-04-21       Impact factor: 13.569

3.  Can we decloak how infections drive complications after lung transplantation?

Authors:  Hrishikesh S Kulkarni; Erika D Lease
Journal:  J Heart Lung Transplant       Date:  2021-05-29       Impact factor: 13.569

Review 4.  Recent advances in lung transplantation.

Authors:  Keith C Meyer
Journal:  F1000Res       Date:  2018-10-23

5.  2018 ATS BEAR Cage Winning Proposal: Cell-Free DNA to Improve Lung Transplant Outcomes.

Authors:  Sean Agbor-Enoh
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

Review 6.  Bacterial infections in lung transplantation.

Authors:  Margaret McCort; Erica MacKenzie; Kenneth Pursell; David Pitrak
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

Review 7.  Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions.

Authors:  Allan R Glanville; Christian Benden; Anne Bergeron; Guang-Shing Cheng; Jens Gottlieb; Erika D Lease; Michael Perch; Jamie L Todd; Kirsten M Williams; Geert M Verleden
Journal:  ERJ Open Res       Date:  2022-07-25

Review 8.  Infection prophylaxis and management of fungal infections in lung transplant.

Authors:  Armelle Pérez-Cortés Villalobos; Shahid Husain
Journal:  Ann Transl Med       Date:  2020-03

Review 9.  Host and Pathogen Communication in the Respiratory Tract: Mechanisms and Models of a Complex Signaling Microenvironment.

Authors:  Samuel B Berry; Amanda J Haack; Ashleigh B Theberge; Susanna Brighenti; Mattias Svensson
Journal:  Front Med (Lausanne)       Date:  2020-09-10

10.  Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation.

Authors:  Hrishikesh S Kulkarni; Kevin Tsui; Suraj Sunder; Alex Ganninger; Laneshia K Tague; Chad A Witt; Derek E Byers; Elbert P Trulock; Ruben Nava; Varun Puri; Daniel Kreisel; Thalachallour Mohanakumar; Andrew E Gelman; Ramsey R Hachem
Journal:  Am J Transplant       Date:  2019-12-24       Impact factor: 8.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.